Advertisement

World Journal of Surgery

, Volume 38, Issue 4, pp 813–822 | Cite as

Electrochemotherapy Treatment of Locally Advanced and Metastatic Soft Tissue Sarcomas: Results of a Non-Comparative Phase II Study

  • Luca G. CampanaEmail author
  • Giuseppe Bianchi
  • Simone Mocellin
  • Sara Valpione
  • Laura Campanacci
  • Antonella Brunello
  • Davide Donati
  • Elisabetta Sieni
  • Carlo R. Rossi
Article

Abstract

Aims

Our aim was to evaluate the activity, toxicity, and feasibility of electrochemotherapy (ECT) in patients with soft-tissue sarcomas (STS).

Methods

A two-stage phase II trial was conducted between October 2006 and March 2012. Patients (N = 34) with locally advanced or metastatic STS, unsuitable for standard oncological treatments and with maximum 3-cm deep tumors, received an intravenous bolus of bleomycin (15,000 IU/m2), followed by tumor electroporation according to the European Standard Operating Procedures of ECT. Outcome measures included local response according to response evaluation criteria in solid tumors (RECIST), toxicity and tumor control. Feasibility measures included the accuracy of electrode placement and the intensity of electric current flowing in tumor tissue.

Results

Median tumor size was 4.0 cm (range 2–12). Objective response, assessed on 71 target lesions, was 92.2 % (complete 32.3, 95 % CI 28–64). A total of 15 patients received up to four cycles due to incomplete response, but re-treatment did not significantly improve outcome (p = 0.205). After a median follow-up of 19.3 months, 2-year local control rate was 72.5 %. Median time to local failure (N = 11 patients) was 5.1 months. Tumor response (p = 0.041) and control (p = 0.047) correlated with histological grading. Relevant toxicity consisted of G3 skin ulceration and soft tissue necrosis (35 and 23 % of patients, respectively), although this was manageable on an outpatient basis. The accuracy of electrode placement was 47.1 %, and the adequacy of electroporative current 85.3 %.

Conclusions

ECT may represent an active and safe treatment to achieve local control in advanced STS patients with symptomatic disease. Future research challenges include the improvement of electrode placement and voltage delivery together with the containment of soft tissue toxicity.

Keywords

Soft Tissue Sarcoma Pazopanib Electrode Placement Soft Tissue Sarcoma Patient Advanced Soft Tissue Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Participating investigators: Angelo Ciccarese, Sandra Cappellato, Connie Celentano, Anaesthesiology Section, Sara Galuppo, Luigi Corti, Radiotherapy Section, Antonella Vecchiato, Sarcoma and Melanoma Unit, cared for patients at the Veneto Oncology Institute; Maria Di Fiore, Stefano Bonarelli, Anaesthesiology Section, Stefano Ferrari, Medical Oncology, Andrea Galuppi, Radiotherapy Section (Sant’Orsola Malpighi Hospital of Bologna), cared for patients at the Orthopaedic Oncology Rizzoli Institute. Paolo Del Fiore retrieved demographic data. Romina Spina administered the quality-of-life questionnaire and managed the study-dedicated database. Francesca Deterlizzi analyzed EQ-5D data. The authors gratefully thank Professor Damian Miklavčič and his research group from Ljubljana University, Slovenia, for the fruitful discussions on mechanism of action of electrochemotherapy and currently investigated technical advancements.

Conflict of interest

Luca G. Campana, Giuseppe Bianchi and Carlo R. Rossi were sponsored by IGEA Company for travel and accommodation at the “Electrochemotherapy 2nd International Users’ Meeting”, Bologna, Italy, March 1–2, 2013. No financial benefit was obtained. The other authors declare no conflict of interest.

Supplementary material

268_2013_2321_MOESM1_ESM.doc (38 kb)
Supplementary material 1 (DOC 38 kb)
268_2013_2321_MOESM2_ESM.doc (1 mb)
Supplementary material 2 (DOC 1046 kb)
268_2013_2321_MOESM3_ESM.tif (83 kb)
eFig. 1 Patient reported health status according to the EuroQoL Group (EQ-5D) after electrochemotherapy. a Percentage of patients with problems in one or more of the five dimensions explored by the EQ-5D descriptive system; b Visual analog scale (EQ-VAS) scores (* p = 0.003) (TIFF 82 kb)

References

  1. 1.
    Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I (2008) Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112:1585–1591PubMedCrossRefGoogle Scholar
  2. 2.
    Mir LM, Morsli N, Garbay JR, Billard V, Robert C, Marty M (2003) Electrochemotherapy: a new treatment of solid tumors. J Exp Clin Cancer Res 22:145–148PubMedGoogle Scholar
  3. 3.
    Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM (1993) Electrochemotherapy, a new antitumour treatment. First clinical phase I-II trial. Cancer 72:3694–3700PubMedCrossRefGoogle Scholar
  4. 4.
    Gehl J, Geertsen PF (2000) Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 10:585–589PubMedCrossRefGoogle Scholar
  5. 5.
    Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T et al (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15:45–51PubMedCrossRefGoogle Scholar
  6. 6.
    Heller R, Gilbert R, Jaroszeski MJ (1999) Clinical applications of electrochemotherapy. Adv Drug Deliv Rev 35:119–129PubMedCrossRefGoogle Scholar
  7. 7.
    Mir LM, Devauchelle P, Quintin-Colonna F et al (1997) First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br J Cancer 76:1617–1622PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Hyacinthe M, Jaroszeski MJ, Dang VV et al (1999) Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer 85:409–417PubMedCrossRefGoogle Scholar
  9. 9.
    Horiuchi A, Nikaido T, Mitsushita J et al (2000) Enhancement of antitumour effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. Int J Cancer 88:640–644PubMedCrossRefGoogle Scholar
  10. 10.
    Sersa G, Jarm T, Kotnik T et al (2008) Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 98:388–398PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Shimizu T, Nikaido T, Gomyo H et al (2003) Electrochemotherapy for digital chondrosarcoma. J Orthop Sci 8:248–251PubMedCrossRefGoogle Scholar
  12. 12.
    de Bree R, Tijink BM, van Groeningen CJ, Leemans CR (2006) Electroporation therapy in soft tissue sarcoma: a potentially effective novel treatment. Sarcoma 85234. doi: 10.1155/SRCM/2006/85234
  13. 13.
    Curatolo P, Quaglino P, Marenco F et al (2012) Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 19:192–198PubMedCrossRefGoogle Scholar
  14. 14.
    Latini A, Bonadies A, Trento E et al (2012) Effective treatment of Kaposi’s sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol Ther 25:214–218PubMedCrossRefGoogle Scholar
  15. 15.
    Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, Geertsen PF, Rudolf Z, O’Sullivan GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator by means of invasive or non-invasive electrodes. EJC Suppl 4:14–25CrossRefGoogle Scholar
  16. 16.
    The EuroQoL Group (1990) EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefGoogle Scholar
  17. 17.
    Corovic S, Al Sakere B, Haddad V, Miklavcic D, Mir LM (2008) Importance of contact surface between electrodes and treated tissue in electrochemotherapy. Technol Cancer Res Treat 7:393–400PubMedGoogle Scholar
  18. 18.
    Marty M, Sersa G, Garbay J et al (2006) Electrochemotherapy—an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 4:3–13CrossRefGoogle Scholar
  19. 19.
    Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372–1383PubMedCrossRefGoogle Scholar
  20. 20.
    Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G (1998) The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 74(5):2152–2158PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Kos B, Zupanic A, Kotnik T, Snoj M, Sersa G, Miklavcic D (2010) Robustness of treatment planning for electrochemotherapy of deep-seated tumours. J Membr Biol 236:147–153PubMedCrossRefGoogle Scholar
  22. 22.
    Miklavčič D, Pavšelj N, Hart FX 2006) Electric properties of tissues. Wiley Encyclopedia of Biomedical Engineering. Wiley. doi:  10.1002/9780471740360.ebs0403
  23. 23.
    Deneve JL, Zager JS (2012) Isolated regional therapy for advanced extremity soft tissue sarcomas. Surg Oncol Clin N Am 21:287–299PubMedCrossRefGoogle Scholar
  24. 24.
    Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V et al (2009) Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 16:191–199PubMedCrossRefGoogle Scholar
  25. 25.
    Campana LG, Valpione S, Falci C et al (2012) The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat 134:1169–1178PubMedCrossRefGoogle Scholar
  26. 26.
    Mali B, Miklavcic D, Cemazar M et al (2013) Tumour size and effectiveness of electrochemotherapy. Radiol Oncol 47:32–41PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Judson I, Verweij J, Gelderblom H et al (2012) Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC soft tissue and bone sarcoma group. Abstract LBA7. Ann Oncol. doi: 10.1093/annonc/mds499 Google Scholar
  28. 28.
    Gehl J, Skovsgaard T, Mir LM (1998) Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 9:319–325PubMedCrossRefGoogle Scholar
  29. 29.
    Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P (2011) Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 22:1266–1272PubMedCrossRefGoogle Scholar
  30. 30.
    Tepper JE, Suit HD (1985) Radiation therapy alone for sarcoma of soft tissue. Cancer 56:475–479PubMedCrossRefGoogle Scholar
  31. 31.
    Jarm T, Cemazar M, Miklavcic D, Sersa G (2010) Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 10:729–746PubMedCrossRefGoogle Scholar
  32. 32.
    Sleijfer S, Gorlia T, Lamers C et al (2012) Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer 107:639–645PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Rossi CR, Vecchiato A, Mastrangelo G, Montesco MC, Russano F, Mocellin S et al (2013) Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann Oncol 24:1685–1691PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2013

Authors and Affiliations

  • Luca G. Campana
    • 1
    Email author
  • Giuseppe Bianchi
    • 2
  • Simone Mocellin
    • 3
  • Sara Valpione
    • 4
  • Laura Campanacci
    • 2
  • Antonella Brunello
    • 5
  • Davide Donati
    • 2
  • Elisabetta Sieni
    • 6
  • Carlo R. Rossi
    • 1
  1. 1.Sarcoma and Melanoma UnitVeneto Institute of Oncology (IOV-IRCCS)PaduaItaly
  2. 2.Oncologic, Orthopaedic and Trauma SurgeryRizzoli Orthopaedic InstituteBolognaItaly
  3. 3.Surgery Branch, Department of Surgery Oncology and GastroenterologyUniversity of PadovaPaduaItaly
  4. 4.Medical Oncology SchoolUniversity of PadovaPaduaItaly
  5. 5.Medical Oncology-IVeneto Institute of Oncology (IOV-IRCCS)PaduaItaly
  6. 6.Department of Industrial EngineeringUniversity of PadovaPaduaItaly

Personalised recommendations